Ligand Pharmaceuticals Incorporated entered into an agreement to acquire APEIRON Biologics AG for $128 million.
The transaction is subject to approval of merger agreement by by boards of Ligand and APEIRON. The deal has been unanimously approved by both the boards. The transaction is subject to a 30-day shareholder objection period and other customary closing conditions and is expected to close in July 2024.
McDermott Will & Emery LLP and E&H Rechtsanwälte GmbH acted as legal advisors to Ligand Pharmaceuticals Incorporated. Baker & McKenzie Diwok Hermann Petsche Rechtsanwälte LLP & Co KG and Dorda Brugger Jordis Rechtsanwälte GmbH acted as legal advisors to APEIRON Biologics AG.